Semaglutide and Tirzepatide Post-Sleeve Gastrectomy Linked to Atypical Anorexia Nervosa in Obese Patient
Background
While severe obesity and Type 2 Diabetes (T2DM) are increasingly managed with bariatric surgery and highly effective incretin-based therapies, the combined impact on mental health requires scrutiny. Dual GLP-1 and GIP receptor agonists like tirzepatide, alongside GLP-1 agonists such as semaglutide, induce significant weight loss through potent appetite suppression. However, the intersection of these powerful pharmacotherapies with bariatric surgery, particularly regarding potential psychiatric sequelae like eating disorders, remains an area requiring careful clinical attention and further understanding. This case highlights a critical gap in monitoring for such adverse events.
Study Design
This case report details a 60-year-old Japanese woman with severe obesity (initial weight 113 kg, BMI 47.0) and Type 2 Diabetes. At 57 years of age, she underwent laparoscopic sleeve gastrectomy. One month post-surgery, treatment with semaglutide and tirzepatide was initiated. The specific doses and administration routes for semaglutide and tirzepatide were not detailed in the abstract. The patient's clinical course was followed for three years post-surgery and initiation of incretin therapy, monitoring for weight changes and psychological symptoms indicative of eating disorders.
Results
Over three years post-surgery and initiation of semaglutide and tirzepatide, the patient experienced a drastic weight reduction from 113 kg to 50.3 kg. Her BMI decreased from 47.0 to 20.9, moving from severe obesity to a normal weight range. This significant weight loss was accompanied by profound psychological changes. > This rapid weight reduction, coupled with an intense fear of weight gain, an obsession with her body image, and a normal BMI (>18.5), led to a diagnosis of atypical anorexia nervosa according to DSM-5 criteria. The case highlights that despite achieving a healthy BMI, the psychological components of an eating disorder can manifest, particularly after significant weight loss interventions combining surgery and potent pharmacotherapy. This outcome underscores the need for comprehensive psychiatric assessment in patients undergoing such aggressive weight management strategies.
Key Findings
- A 60-year-old woman developed atypical anorexia nervosa after sleeve gastrectomy and incretin therapy.
- She experienced a drastic weight reduction from 113 kg (
BMI 47.0) to 50.3 kg (BMI 20.9). - Diagnosis was based on rapid weight loss, intense fear of weight gain, body image obsession, and normal
BMI(>18.5). - The case highlights potential psychiatric risks of combined bariatric surgery and
GLP-1/GIPagonist treatment.
Why It Matters
This case underscores the critical need for enhanced psychiatric screening and ongoing monitoring for eating disorders in patients receiving highly effective weight loss therapies, especially post-bariatric surgery. For peptide users and clinicians, it highlights that while GLP-1/GIP agonists are powerful tools for obesity, their use, particularly in combination with surgery, necessitates vigilance for psychological side effects like atypical anorexia nervosa. This isn't about changing dosing protocols directly but rather emphasizing the importance of a holistic patient assessment that includes mental health. Integrating mental health support and education into weight management programs involving these potent peptides is crucial to prevent severe psychological complications, even when physical health metrics improve.